Institutional review board

BTAI LAWSUIT ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Tuesday, July 25, 2023
CASE, LLP, Institutional review board, Telephone, COST, Record, Levi, Dementia, Patient, CLASS, NEXT, Court, FDA, Therapy, Agitation, Safety, Cryptocurrency

NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were adversely affected by alleged securities fraud between December 15, 2021 and June 28, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    BTAI investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.

Retrieved on: 
Tuesday, July 25, 2023
LLP, Institutional review board, Record, Food and Drug Administration Amendments Act of 2007, Dementia, District court, Patient, Advertising, Complaint, Defendant, Court, Action Replay, FDA, Therapy, News, Agitation, Food, Safety, Cryptocurrency, Pharmaceutical industry, Security (finance)

If you purchased or acquired BioXcel securities, and/or would like to discuss your legal rights and options please visit BioXcel Therapeutics, Inc.

Key Points: 
  • If you purchased or acquired BioXcel securities, and/or would like to discuss your legal rights and options please visit BioXcel Therapeutics, Inc.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you purchased or acquired BioXcel securities, and/or would like to discuss your legal rights and options please visit BioXcel Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

BioXcel Therapeutics, Inc: Please contact the Portnoy Law Firm to recover your losses; September 5, 2023 deadline

Retrieved on: 
Monday, July 24, 2023
Institutional review board, Maintenance, Record, Dementia, Patient, Defendant, FDA, Therapy, Agitation, Pharmaceutical industry

​LOS ANGELES, July 24, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI). investors that a lawsuit filed on behalf of investors that purchased BioXcel securities between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”).

Key Points: 
  • ​LOS ANGELES, July 24, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

BTAI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc. Shareholders

Retrieved on: 
Monday, July 24, 2023
Institutional review board, Telephone, COST, Record, HOW, Dementia, Patient, CLASS, FDA, Therapy, Agitation, Safety, Pharmaceutical industry

NEW YORK, July 24, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws.

Key Points: 
  • NEW YORK, July 24, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws.
  • WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in BioXcel you have until September 5, 2023 to petition the court for lead plaintiff status.
  • Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
  • HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the BTAI lawsuit, please contact J. Klein, Esq.

Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!

Retrieved on: 
Monday, July 24, 2023
Institutional review board, Record, Person, Dementia, Patient, Complaint, Defendant, Court, FDA, Therapy, Agitation, Safety, Pharmaceutical industry

Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/btai .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/btai .
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • If you suffered a loss in BioXcel you have until September 5, 2023, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI

Retrieved on: 
Saturday, July 22, 2023
Titan, Institutional review board, Dexmedetomidine, Class, Record, Agitation, Dementia, Patient, Advertising, Court, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, I-Space (Chinese company), Food, Safety, Insurance, Tobacco

WHAT TO DO NEXT: To join the BioXcel Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=17579 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioXcel Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=17579 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

BTAI INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Saturday, July 22, 2023
FOX, Record, Person, Institutional review board, Kaplan Fox, Complaint, Food and Drug Administration, Dementia, Notice, Patient, Artificial intelligence, FDA, Therapy, News, Agitation, Food, Cryptocurrency, Pharmaceutical industry

If you acquired BioXcel securities during the Class Period and would like to discuss this case, please click here .

Key Points: 
  • If you acquired BioXcel securities during the Class Period and would like to discuss this case, please click here .
  • WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.
  • With over 50 years of experience in complex litigation, Kaplan Fox offers the professional experience and track record that clients demand.
  • For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com .

DEADLINE ALERT for BTAI, MNK, STX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Friday, July 21, 2023
Acceleration, People's Law Office, Mallinckrodt, Institutional review board, BIS, Privacy Office of the U.S. Department of Homeland Security, Chapter 11, Title 11, United States Code, Class, Software, Telephone, Trust, Record, Law, Seagate, Suite, Dementia, Investment, Patient, Nature, Risk, FDA, Science and technology in Asia, Agitation, Safety, Commerce, U.S. Department of Commerce Office of Security, Security (finance), Huawei

BENSALEM, Pa., July 21, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., July 21, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

BTAI LAWSUIT ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Friday, July 21, 2023
CASE, LLP, Institutional review board, Telephone, COST, Record, Levi, Dementia, Patient, CLASS, NEXT, Court, FDA, Therapy, Agitation, Safety, Cryptocurrency

NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were adversely affected by alleged securities fraud between December 15, 2021 and June 28, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    BTAI investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages BioXcel Therapeutics (BTAI) Investors with Substantial Losses to Contact Firm’s Attorney, Securities Fraud Class Action Filed

Retrieved on: 
Friday, July 21, 2023
Institutional review board, Alzheimer's disease, Person, Record, Patient, Hagens Berman, SAN, Defendant, FDA, Therapy, News, Safety, Protocol, Pharmaceutical industry, Medical device

SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now .
  • BioXcel Therapeutics, Inc. (BTAI) Securities Fraud Class Action:
    The litigation focuses on BioXcel’s statements and omissions regarding its TRANQUILITY II study evaluating its Alzheimer candidate drug BXCL501.
  • “We’re focused on investors’ losses and proving BioXcel misled investors about its adherence to the trial protocol and the true commercial prospects for BXCL501,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in BioXcel and have substantial losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .